Masaharu Noi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Masaharu Noi has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Gaku Yamamoto
Department of Oral and Maxillofacial Surgery, Shiga University of Medical Science
2 shared publicationsYoshisato Machida
Department of Oral and Maxillofacial Surgery, Shiga University of Medical Science
2 shared publicationsHiroyuki Sugihara
Division of Molecular Diagnostic Pathology, Department of Pathology, Shiga University of Medical Science, Otsu, Japan
1 shared publication- Ken-Ichi Mukaisho
Education Center for Medicine and Nursing Shiga University of Medical Science Otsu Japan
1 shared publication Masashi Yamori
Department of Oral and Maxillofacial Surgery, Shiga University of Medical Science, Otsu, Japan
1 shared publication- Masashi Yamori
Department of Oral and Maxillofacial Surgery, Shiga University of Medical Science, Shiga, Japan
1 shared publication
Latest Publications
- Open Access
- 20 May 2020
- Published by Japanese Society of Oral and Maxillofacial Surgeons in Japanese Journal of Oral and Maxillofacial Surgery
- Vol. 66 (5) , 240-245
A case of lung adenosquamous carcinoma initially detected as metastasis to the mandibular gingiva
Metastatic tumors from other organs to the oral and maxillofacial region are relatively rare. To the best of our knowledge, only six cases of oral metastatic tumors from lung adenosquamous carcinomas have been reported in Japan to date. Here we report a case of lung adenosquamous carcinoma that was initially detected as a metastatic tumor of the gingiva. An 80-year-old man presented with a tumor on the gingiva in the right mandibular region. The differential diagnoses following an incisional biopsy were poorly-differentiated adenocarcinoma, nonkeratinizing squamous cell carcinoma, and poorly-differentiated mucoepidermoid carcinoma. Positron emission tomography-computed tomography revealed abnormal accumulations in the right mandible, right cervical lymph nodes, right lung and regional lymph nodes, and stomach. Lung biopsy revealed that the primary tumor was lung cancer (adenosquamous carcinoma) that had metastasized to the mandibular gingiva. Four courses of carboplatin plus a nonplatinum-based regimen were provided, but the patient presented with progressive disease. Similar findings were observed after a second treatment with three courses of S-1 chemotherapy. Despite the provision of the best supportive care, the general condition of the patient worsened, and he eventually died.
- 20 May 2020
- Published by Japanese Society of Oral and Maxillofacial Surgeons in Japanese Journal of Oral and Maxillofacial Surgery
- Vol. 66 (5) , 240-245
Open AccessA case of lung adenosquamous carcinoma initially detected as metastasis to the mandibular gingiva
Metastatic tumors from other organs to the oral and maxillofacial region are relatively rare. To the best of our knowledge, only six cases of oral metastatic tumors from lung adenosquamous carcinomas have been reported in Japan to date. Here we report a case of lung adenosquamous carcinoma that was initially detected as a metastatic tumor of the gingiva. An 80-year-old man presented with a tumor on the gingiva in the right mandibular region. The differential diagnoses following an incisional biopsy were poorly-differentiated adenocarcinoma, nonkeratinizing squamous cell carcinoma, and poorly-differentiated mucoepidermoid carcinoma. Positron emission tomography-computed tomography revealed abnormal accumulations in the right mandible, right cervical lymph nodes, right lung and regional lymph nodes, and stomach. Lung biopsy revealed that the primary tumor was lung cancer (adenosquamous carcinoma) that had metastasized to the mandibular gingiva. Four courses of carboplatin plus a nonplatinum-based regimen were provided, but the patient presented with progressive disease. Similar findings were observed after a second treatment with three courses of S-1 chemotherapy. Despite the provision of the best supportive care, the general condition of the patient worsened, and he eventually died.
- Open Access
- 13 April 2020
- Published by Wiley in Clinical and Experimental Dental Research
- Vol. 6 (4) , 420-427
Expressions of ezrin, ERK, STAT3, and AKT in tongue cancer and association with tumor characteristics and patient survival
Background: Ezrin, ERK, STAT3, and AKT are proteins that are overexpressed in various types of cancer, although their expressions in tongue cancer has received less focus. This study aimed to address associations between the expression levels of these proteins and with characteristics of the tumor and patient survival.Methods: We performed immunohistochemical staining of ezrin, ERK, STAT3, and AKT in tumors from patients with tongue carcinoma in situ (CIS, n = 17) and tongue squamous cell carcinoma (SCC, n = 46). Statistical differences between the SCC versus the CIS cohorts were estimated by calculations of bivariate odds ratios of low versus high expression of the proteins. Fisher's exact tests were used to appraise interassociations between the proteins, as well as expression levels versus patient and tumor characteristics. Survival based on Kaplan–Meier statistics in combination log‐rank tests were used to address potential effects of the patient and tumor characteristics versus 5‐year survival rate.Results: The relative high: low expression of all four proteins in the two cohorts differed, and particularly ERK was markedly overexpressed in the SCC versus the CIS cohort (odds ratio = 45.3, p < .01). The relative high: low expression each protein versus patient and tumor characteristics; showed associations between AKT expression and T stage (p = .002) plus node metastases (p = .12), and between ERK expression and drinking (p = .01) and smoking history (p = .01). There was no significant difference observed between ERK and the three other molecules, nor any significant difference between the degree of expression of each protein and the 5‐year disease‐specific survival rate.Conclusion: Ezrin, ERK, STAT3, and AKT appear to be involved in the progress from carcinoma in situ in the tongue into squamous cell carcinoma. ERK in particular is overexpressed, suggesting that ERK may be a novel therapeutic target for preventing tongue cancer.
- 13 April 2020
- Published by Wiley in Clinical and Experimental Dental Research
- Vol. 6 (4) , 420-427
Open AccessExpressions of ezrin, ERK, STAT3, and AKT in tongue cancer and association with tumor characteristics and patient survival
Background: Ezrin, ERK, STAT3, and AKT are proteins that are overexpressed in various types of cancer, although their expressions in tongue cancer has received less focus. This study aimed to address associations between the expression levels of these proteins and with characteristics of the tumor and patient survival.Methods: We performed immunohistochemical staining of ezrin, ERK, STAT3, and AKT in tumors from patients with tongue carcinoma in situ (CIS, n = 17) and tongue squamous cell carcinoma (SCC, n = 46). Statistical differences between the SCC versus the CIS cohorts were estimated by calculations of bivariate odds ratios of low versus high expression of the proteins. Fisher's exact tests were used to appraise interassociations between the proteins, as well as expression levels versus patient and tumor characteristics. Survival based on Kaplan–Meier statistics in combination log‐rank tests were used to address potential effects of the patient and tumor characteristics versus 5‐year survival rate.Results: The relative high: low expression of all four proteins in the two cohorts differed, and particularly ERK was markedly overexpressed in the SCC versus the CIS cohort (odds ratio = 45.3, p < .01). The relative high: low expression each protein versus patient and tumor characteristics; showed associations between AKT expression and T stage (p = .002) plus node metastases (p = .12), and between ERK expression and drinking (p = .01) and smoking history (p = .01). There was no significant difference observed between ERK and the three other molecules, nor any significant difference between the degree of expression of each protein and the 5‐year disease‐specific survival rate.Conclusion: Ezrin, ERK, STAT3, and AKT appear to be involved in the progress from carcinoma in situ in the tongue into squamous cell carcinoma. ERK in particular is overexpressed, suggesting that ERK may be a novel therapeutic target for preventing tongue cancer.